Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692348 | 0.88 | MEN1 (0.49) | MAPK1MAPK14KMT2AMEN1 | |
| SCHEMBL692489 | 0.84 | MAPK14 (0.45) | POLBMAPK14KMT2AHPGDALDH1A1 | |
| SCHEMBL690195 | 0.83 | AKR1C2 (0.46) | MAPK1MAPK14HPGDALDH1A1LMNA | |
| SCHEMBL9613113 | 0.82 | MAPK14 (0.46) | MAPK1MAPK14HPGDALDH1A1LMNA | |
| SCHEMBL690828 | 0.81 | SMN1; SMN2 (0.48) | TP53POLBKMT2AHPGDMEN1 | |
| SCHEMBL692220 | 0.81 | HIF1A (0.47) | ALDH1A1 | |
| SCHEMBL692237 | 0.80 | PTPN7 (0.42) | MAPK1THRBLMNA | |
| SCHEMBL1114466 | 0.79 | ALDH1A1 (0.46) | MAPK1TP53POLBKMT2AHPGD | |
| SCHEMBL692923 | 0.78 | FFAR1 (0.45) | MAPK14 | |
| SCHEMBL690181 | 0.77 | P2RX1 (0.42) | TP53POLBTHRBHTTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | MAPK1 2718/4885TP53 1900/4885POLB 3401/4885 |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | ORAI1, ATP2A3, ANO1 | MAPK1 2523/4885TP53 3985/4885POLB 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.